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Endothelial dysfunction seems to be a key factor in the development of several complications observed early
after hematopoietic stem cell transplantation (HSCT). The conditioning regimen and many other factors
associated with the procedure are responsible for this endothelial damage. The effects of immunosuppressive
agents on endothelial function have not been explored in detail. We evaluated the effects of 3 drugs
commonly used in HSCT: 2 calcineurin inhibitors, cyclosporine A (CSA) and tacrolimus (TAC), and an inhibitor
of mTOR, sirolimus (SIR). We also evaluated the effect of the combination of TAC and SIR (TACþSIR), which is
used increasingly in clinical practice. Microvascular endothelial cells (HMEC-1) were exposed to these drugs
to evaluate changes in (1) intercellular adhesion molecule (ICAM)-1 expression on the cell surface, assessed
by immunoﬂuorescence labeling and expressed as the mean gray value (MGV); (2) reactivity of the extra-
cellular matrix (ECM) toward platelets, upon exposure of the ECM to circulating blood; and (3) whole-blood
clot formation, assessed by thromboelastometry. Studies were conducted in the absence and presence of
deﬁbrotide (DF) to assess its possible protective effect. The exposure of HMEC-1 to CSA and TACþSIR
signiﬁcantly increased the expression of ICAM-1 (157.5  11.6 and 153.4  9.5 MGV, respectively, versus
105.7  6.5 MGV in controls [both P < .05]). TAC applied alone increased ICAM-1 slightly (120.3  8.2 MGV),
and SIR had no effect (108.9  7.4 MGV). ECM reactivity increased signiﬁcantly only in response to CSA
(surface covered by platelets of 41.2%  5.4% versus 30.1%  2.0%, P < .05). DF attenuated all these changes. No
signiﬁcant changes in the viscoelastic properties of clot formation were observed in any condition with blood
samples incubated in vitro. In conclusion, CSA and TACþSIR had a proinﬂammatory effect, but only CSA
exhibited an additional prothrombotic effect. Interestingly, DF exerted clear protective anti-inﬂammatory and
antithrombotic effects on the endothelium.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a well-
established therapeutic option for several hematological
malignancies and other nonmalignant disorders. HSCT is
associated with life-threatening complications that may
appear soon after transplantation. Some of these complica-
tions, such as veno-occlusive disease (VOD), thrombotic
microangiopathy (TMA), engraftment syndrome, and capil-
lary leak syndrome, among others [1], seem to be triggered
by endothelial damage.
Using a macrovascular cell model, our group demon-
strated the presence of endothelial damage in both alloge-
neic and autologous HSCT [2,3]. This endothelial damage is
characterized by an increase in the expression of adhesion
receptors on the cell surface, leukocyte adhesion when cells
are exposed to circulating blood, and activation of p38
mitogen-activated protein kinase. Factors released during
HSCT stimulate endothelial cells to produce a more pro-
thrombotic extracellular matrix (ECM), enriched with vondgments on page 1444.
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increased adhesion of platelets when these surfaces are
exposed to blood under ﬂow conditions. These observations
were also reproduced in a microvascular cell model that was
exposed to sera from patients who received an autologous
HSCT. In this particular approach, we were able to demon-
strate a protective effect of deﬁbrotide [DF] [4].
The activation of and damage to endothelial cells during
HSCT are caused by different factors, including chemo-
radiotherapy used as a conditioning regimen, cytokines
produced by the injured tissues, bacterial endotoxins trans-
located through the damaged gastrointestinal tract, the
complex process of engraftment, and allogeneic reactions
with the donor-derived immune cells. Some drugs
used during the procedure, such as granulocyte colony-
stimulating factor [5] and immunosuppressant therapy, can
contribute to this damage. Although there is evidence of the
toxic or deleterious effect on the endothelium caused by
cyclosporine A (CSA) [6-8], it is still the immunosuppressive
drug of choice in HSCT. There is little information on the
effect on the endothelium of other immunosuppressive
drugs used in HSCT [9,10]. The knowledge acquired from
other clinical situations, such as kidney transplantation,
indicates that some agents aremore toxic to the endothelium
than others [11]. The long-term follow-up of patientsTransplantation.
A. Carmona et al. / Biol Blood Marrow Transplant 19 (2013) 1439e14451440receiving HSCT has shown a very high incidence of vascular
complications (eg, cerebral stroke, ischemia, lacunar defects,
coronary angina, infarction, peripheral claudication,
ischemia, pain, and gangrene) [12]. It is thus reasonable to
question whether these agents, administered for months or
years after transplantation, play a role in such pathogenesis.
The aim of the present studywas to evaluate and compare
the effects of the calcineurin inhibitors, CSA and tacrolimus
(TAC), and the mTOR (mammalian Target of Rapamycin)
inhibitor sirolimus (SIR) on the endothelium in a cell culture
model. The combined use of TAC and SIR (TACþSIR) was also
assessed because it seems to be associated with a higher
incidence of TMA [13-15] and VOD [16,17], depending on the
conditioning regimen. The potential protective effect of DF
was also explored in this setting. To do this, we applied the
experimental approach used in our previous studies aimed at
evaluating changes related to inﬂammation and thrombosis.
METHODS
Experimental Design
An immortalized human microvascular endothelial cell line was inde-
pendently exposed in culture to CSA and TAC, 2 calcineurin inhibitors, and
SIR, an mTOR inhibitor. In some experiments, cells were exposed simulta-
neously to TACþSIR. Changes in both the expression of the intercellular
adhesion molecule (ICAM)-1 at the cell surface and the adhesion of platelets
on the ECM generated by these cells under ﬂow conditions were assessed.
The effect of DF was explored by incubating the cells with 100 mg/mL DF for
24 hours before exposing the cells to the immunosuppressive drugs and
during the exposure to these drugs. The effect of the drugs included in the
study was also explored by measuring changes in the thromboelastometric
properties of blood.
Human Endothelial Cell Culture
The human microvascular endothelial cell line CDC/EU.-HMEC-1
(henceforth referred to as HMEC-1 cells) [18] was grown at 37C in a 5%
CO2 humidiﬁed incubator in MDCB131 medium (Gibco BRLeLife Technolo-
gies, Barcelona, Spain) supplemented with 4% L-glutamine, 1% pen-
icillinestreptomycin (Gibco BRLeLife Technologies), 2 mg/mL hydrocortisone
(Sigma-Aldrich Quimica SA, Madrid, Spain), 10 ng/mL epidermal growth
factor (BD Biosciences, Erembodegem, Belgium), and 10% FBS (Gibco
BRLeLife Technologies). Culture medium was replaced every day. To study
the effect of the different compounds, CSA, TAC, or SIR were added at a ﬁnal
concentration of 200 ng/mL, 10 ng/mL, or 10 ng/mL, respectively. In the
experiments with TACþSIR, the same ﬁnal concentration for each substance
was used. These concentrations were chosen based on blood levels achieved
in clinical practice. Cells were ﬁnally cultured on 1% gelatin-coated glass
coverslips (18  18 mm2).
HMEC-1 cultures were grown in the absence or presence of DF added
every 24 hours. The DF concentrationwas based on the dose used in vivo for
therapy [19] and after review of the literature on in vitro studies [20,21].
Immunoﬂuorescence Detection of ICAM-1 on the Endothelial Cell
Surface
Cells were seeded into 6-well plates containing 18  18 mm2 coverslips
and exposed to the immunosuppressive drugs for 24 hours. In conditions in
which DF was included, the cells were preincubated with DF for 24 hours
before exposure to the immunosuppressant. Cells were ﬁxed with 4%
paraformaldehyde in 0.15 M PBS (pH 7.4) for 10 minutes at 4C. The ﬁxed
coverslips were then incubated with a speciﬁc monoclonal antibody
(MAB2146; Chemicon International, Temecula, CA) (dilution 1:200) for
1 hour at room temperature. The excess antibody was removed by washing
3 times with PBS, and the coverslips were incubated with a donkey anti-
mouse IgG conjugated with Alexa Fluor 555 (Molecular Probes, New York,
NY) (dilution 1:2000) for 1 hour at room temperature. Finally, the samples
were evaluated by light microscopy (Leica DM4000 B, Barcelona, Spain)
using appropriate ﬁlters, and images were captured using a video camera
(Leica DFC310 FX, Barcelona, Spain). Fluorescence micrographs were
analyzed densitometrically using Image J software (version 1.43 m; National
Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/nih-image/
manual/tech.html#analyze). This software automatically analyzes the gray
density of each pixel in a scale ranging from 0 (black) to 255 (white).
Cultured cells were selected from the background with the threshold tool,
and the ﬂuorescence intensity was measured only in the selected area.
Results are expressed as mean gray value (MGV).Perfusion Studies
HMEC-1monolayers were grown on glass coverslips for 7 days and then
extracted by treatment with 6% EGTA (1 hour at 37C) to expose the ECM on
the coverslips. Perfusion studies to evaluate platelet adhesion were per-
formed in a parallel-plate perfusion chamber at a shear rate of 800/s for
5 minutes [22-24], in which the ECM-coated coverslips were exposed to
25-mL aliquots of citrated whole blood (at a ﬁnal citrate concentration of
19 mM) from a healthy donor. After perfusion, the coverslips were rinsed
with 0.15 M PBS, ﬁxed with 0.5% glutaraldehyde in 0.15 M PBS at 4C for
24 hours, and stained with 0.02% toluidine blue. The degree of platelet
deposition was measured in 10 microscopic ﬁelds per coverslip and was
evaluated en face using an automated method [22]. The surface covered by
platelets is expressed as a percentage relative to the total area of the
coverslip screened (%SC).
Thromboelastometry Studies
To evaluate in vitro the effects of the immunosuppressive drugs in the
absence and presence of DF on whole-blood clot formation, we used
a ROTEM thromboelastometry analyzer (Pentapharm GmbH, Munich,
Germany) to perform dynamic thromboelastometry of whole-blood coag-
ulation [25] according to the manufacturer’s instructions. We used the
commercial test EXTEM (Pentapharm GmbH, Munich, Germany) to measure
changes in the extrinsic pathway of coagulation, ﬁbrinogen and ﬁbrin
polymerization, and platelet function. Clots obtained in the EXTEM
comprised platelets and ﬁbrin. We recorded the clotting time and clot
formation time (CFT), which indicated the dynamics of clot formation, and
maximum clot ﬁrmness, which gave information about clot strength and
stability, andwas largely dependent on ﬁbrinogen and platelets. The clotting
time was deﬁned as the time when the forming clot reached 2 mm; the CFT
was deﬁned as the time when the clot reached 20 mm.
To evaluate the effects of CSA, TAC, SIR, and TACþSIR on the throm-
boelastometric properties of blood, we incubated whole blood with the
immunosuppressive drugs at the concentrations indicated above. In
conditions in which DF was added, the blood samples were preincubated
with 100 mg/mL DF for 30 minutes.
Statistical Analysis
Results are expressed as means  SEM. Statistical analysis was per-
formed with raw data using Student’s t-tests for paired and unpaired
samples. The results were considered signiﬁcant at P < .05.
RESULTS
Proliferation of HMEC-1 in the Presence of
Immunosuppressive Drugs
In the HMEC-1 monolayers, microscopic observation
showed no changes in the proliferation kinetics in the
presence of CSA or TAC. However, in the presence of SIR,
HMEC-1 monolayers were rarely conﬂuent and fewer
dividing cells were seen. The percentage of dividing cells
relative to the total number of cells present was calculated in
each microscopic ﬁeld, which comprised 10 ﬁelds per
experiment. The percentages were 0.1% 0.2% in response to
SIR versus 1.0%  0.1% in control experiments (P < .001)
(Figure 1). Interestingly, preincubation with DF minimized
the inhibitory effect of SIR on cell proliferation.
Changes in the Expression of ICAM-1 in Cell Monolayers
Expression of ICAM-1 increased signiﬁcantly in HMEC-1
monolayers treated with CSA (157.5  11.6 MGV in treated
cells versus 105.7  6.5 MGV in control monolayers, P < .05;
expressed asmean SEMmeasured by densitometry; n¼ 5).
Only a small increase in ICAM-1 expression was observed in
cells exposed to TAC (120.3  8.2 MGV, n ¼ 5), and almost no
effect was observed in response to SIR (108.9  7.4 MGV,
n ¼ 5). The combination TACþSIR showed a markedly
increased ICAM-1 expression (153.4 9.5MGV, n¼ 5, P< .05
versus control) to a level greater than that obtained for each
immunosuppressive drug separately (Figure 2). Pre-
incubation of cells with DF attenuated the increase in ICAM-1
expression in cells treated with the immunosuppressive
drugs: CSA (124.9  10.0 MGV, n¼ 5), TAC (102.2  8.8 MGV,
Figure 1. Morphology and growth kinetics of endothelial cells exposed to different immunosuppressants. Micrographs correspond to untreated HMEC-1 monolayers
(C) and cells exposed to cyclosporine A (CSA), tacrolimus (TAC), or sirolimus (SIR). In the presence of SIR, HMEC-1 monolayers were rarely conﬂuent and fewer
dividing cells were seen. Images are representative of 5 different experiments.
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DF was signiﬁcant in the case of CSA (P < .05) and TACþSIR
(P< .05). No signiﬁcant effect of DF itself on the expression of
ICAM-1 was observed (113.3  5.6 MGV versus 105.7  6.5
MGV in control monolayers).Reactivity of the ECM Generated by HMEC-1 Exposed
to Immunosuppressant Drugs
The reactivity toward circulating platelets by the ECM
generated by HMEC-1 cells was evaluated before and after
exposure to the immunosuppressive drugs (Figure 3). In
control experiments, the %SC was 30.1%  2.0% (n ¼ 11).
Exposure to CSA increased the %SC to 41.2%  5.4% (P < .05
versus control). The %SC was lower than the control
percentage after incubation with TAC (23.2%  3.0%), SIR
(21.7%  2.1%), or TACþSIR (26.9  4.8%) (n ¼ 5 for each).
The increased reactivity of the ECM in response to CSA
was attenuated in the presence of DF (25.6%  4.5%, n ¼ 5,
P < .05). The adhesion of platelets to the ECM generated by
HMEC-1was not affected by exposure toTAC, SIR, or TACþSIR
in the presence of DF (23.7%  3.1%, 22.5%  1.7%, and
24.8%  4.9%, respectively). No signiﬁcant effect of DF itself
on the reactivity of the ECM generated by control cells was
observed (27.3  3.5 versus 30.1%  2.0% in controls).Modiﬁcations of the Viscoelastic Properties of Clots:
Thromboelastometry Studies
The lack of effect on the reactivity of the ECM in response to
TAC, SIR, and TACþSIR prompted us to evaluate the effects of
these drugs on clot formationwith samples incubated in vitro
with the drugs under study. The studyof the extrinsic pathway
with the EXTEM test showed no signiﬁcant differences in the
viscoelastic properties of clots (measured as the clotting time,
CFT, and maximum clot ﬁrmness) between the different
conditions (Table 1 and Figure 4). Inwhole blood preincubated
with DF alone or with the immunosuppressive drugs, CFTincreased slightly although not signiﬁcantly (Figure 4), indi-
cating a slightdelay in the formation of clots, although thiswas
always within the normal range of 34 to 159 seconds.DISCUSSION
Our group demonstrated previously that endothelial
damage occurs in association with allogeneic or autologous
HSCT. The degree of endothelial damage observed both
in vivo and in vitro is related directly to the intensity of the
conditioning treatment, among other factors [2,3]. These
factors include substances released by damaged cells, such as
cytokines and chemokines, and treatments given before and
during the HSCT process. The deleterious effects on the
endothelium of CSA, an agent used frequently in allogeneic
HSCT, were reported previously [6-8]. The present work was
performed to compare the effects of 3 different immuno-
suppressive drugs, 2 calcineurin inhibitors, CSA and TAC, and
the mTOR inhibitor SIR. Our results indicate that both calci-
neurin inhibitors have a proinﬂammatory effect, although
only CSA exhibited signiﬁcant proinﬂammatory and pro-
thrombotic effects on the endothelium. By contrast, although
these effects were not observedwith SIR, this mTOR inhibitor
changed the proliferation kinetics and decreased the reac-
tivity of the ECM. Interestingly, DF attenuated the changes
caused by the immunosuppressive drugs evaluated.
Many early complications associated with HSCT seem to
be ascribed to endothelial injury occurring in the microvas-
culature [1]. There is evidence of different behaviors between
immunosuppressants, as shown by analyzing aspects of cell
proliferation, oxidative stress, side effects, and renal func-
tion. Most studies have been performed in animal models or
with solid transplants [9,10].
Our comparison of the effects of CSA, TAC, and SIR
on microvascular endothelial cells indicates that these
cells respond differently to different immunosuppressive
strategies and to the 2 different calcineurin inhibitors tested;
Figure 2. Expression of ICAM-1 on the surface of microvascular endothelial cells (HMEC-1) induced by different immunosuppressive drugs: effect of DF. Micrographs
show ICAM-1 expression on untreated HMEC-1 cells (C) or in cells exposed to cyclosporine A (CSA), tacrolimus (TAC), sirolimus (SIR), or the combination of TAC and
SIR (TACþSIR) in the absence of DF. The bar diagram shows ICAM-1 expression on HMEC-1 cells in response to the immunosuppressive drugs in the absence (black
bars) and presence (gray bars) of DF. Data are expressed as mean  SEM; *P < .05 versus control and #P < .05 versus the drug in the absence of DF.
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[11]. Although both calcineurin inhibitors had a proin-
ﬂammatory effect, which was moderate in the case of TAC,
only CSA exhibited signiﬁcant proinﬂammatory and pro-
thrombotic effects on the endothelium. By contrast, exposure
of cells to SIR did not signiﬁcantly change the expression of
adhesion receptors on the cell surface or generate an ECM
that was more reactive toward platelets. Our results are
consistent with previous data demonstrating that SIR has
few damaging effects on the endothelium. SIR decreases
vascular endothelial growth factor synthesis [26] and seems
to prevent or limit intimal thickening [27]. SIR is the
immunosuppressant of choice for renal transplantation and
is being used more frequently in the HSCT setting. It is also
interesting that SIR-eluting stents produced with different
coating strategies are now used to prevent coronary reste-
nosis because of the ability of SIR to inhibit cell proliferation
[28,29]. The microscopic observations of cells grown in the
presence of SIR in our study conﬁrmed the effect of this drug
on cell division and proliferation.
Numerous clinical trials have shown TAC to be superior to
CSA in the prevention of acute rejection, and trials have
demonstrated the superiority of TAC over CSA in terms of
allograft survival [30,31]. In bone marrow transplantation,
the incidence of grades II to IV graft-versus-host disease wassigniﬁcantly lower with TAC thanwith CSA [32,33]. However,
administration of CSA seems to bemore established than TAC
in the setting of HSCT, and only some centers have replaced
CSA with TAC. The results from our in vitro studies showing
amore deleterious effect of CSA than TAC on endothelial cells
are consistent with previously published observations. In
addition to our results demonstrating both proinﬂammatory
and prothrombotic effects of CSA, another study reported
a stronger induction of oxidative stress after exposure of
HMEC-1 cells to CSA compared with TAC, an effect that
correlated with metabolic activity and apoptosis [10]. In
addition, CSA alters endothelial cell morphology, whereas
TAC does not. The effects of CSA may relate, at least partly, to
increased endothelin release by endothelial cells [34]. Taken
together, these ﬁndings, along with the high incidence of
long-term vascular complications observed after allogeneic
HSCT, lead us to consider abandoning CSA as the immuno-
suppressant of choice for HSCT.
After the introduction of SIR in clinical practice, several
authors reported a higher incidence of transplant-associated
TMA [13-15]. Similarly, an increased incidence of VOD was
observed in both busulfan or cyclophosphamide plus total
body irradiationecontaining regimens [16,17]. Our present
observations suggest that SIR is not the cause of the
increased incidence of TMA and VOD but rather the
Figure 3. Reactivity of the ECM from microvascular endothelial cells grown in the presence of immunosuppressive drugs: effect of DF. (A) Light micrographs show
platelet adhesion and aggregate formation on ECM generated by untreated HMEC-1 cells (C) and cells treated with cyclosporine A (CSA) in the absence and presence
of 100 mg/mL deﬁbrotide (CSA þ DF). (B) The bar diagram shows the percentages of surface covered by platelets (%SC) on the ECM from untreated HMEC-1 cells and
on cells exposed to the immunosuppressive drugs in the absence (black bars) and presence (gray bars) of DF. Data are expressed as mean  SEM; *P < .05 versus
control and #P < .05 versus the drug in the absence of DF.
A. Carmona et al. / Biol Blood Marrow Transplant 19 (2013) 1439e1445 1443combined use of TACþSIR, which explains why some cases of
TMA observed in patients who receive TAC improve when
TAC is substituted by SIR [35].
The combined use of TACþSIR has provided favorable
results by reducing the incidence of graft-versus-host
disease [15,36,37]. Studies comparing different administra-
tion schedules and combinations could be performed to
circumvent the endothelial injury produced by the combined
use of these drugs. Another possible approach may be to
abandon the calcineurin inhibitors and to substitute them
with other combinations of immunosuppressive agents such
as mycophenolate mofetil plus SIR, despite the fact that
initial good results observed after kidney and heart trans-
plantation have not been reproduced in SCT [38,39]. Finally,
it may be possible to attenuate or prevent endothelial injury
by administrating DF during the early phases of HSCT,Table 1
Modiﬁcations on the Viscoelastic Properties of Clots in the Presence of Immunosu
Control CSA TAC SIR TACþSIR
CT
Mean 57.3 58.0 53.1 60.0 58.2
SEM 6.7 10 8.1 9.3 7.9
CFT
Mean 86.3 80.0 76.0 88.7 85.0
SEM 8.9 17.0 11.0 5.2 13.1
MCF
Mean 63.7 65.5 63.7 60.3 62.0
SEM 1.5 3.5 2.9 0.9 3.1
N ¼ 5. Clotting time (CT) is the time when the forming clot reached 2 mm; CFT is th
relates to clot strength and stability.because this drug prevents endothelial injury and addition-
ally seems to decrease the risk of graft-versus-host disease
[40]. DF is a well-tolerated drug that is used successfully for
the treatment [19,41-43] and prophylaxis [40] of VOD. Our
previous in vitro studies demonstrated that DFmay be useful
as a protective agent in both allogeneic and autologous HSCT
[4]. Our present results indicate that DF can attenuate the
damaging proinﬂammatory and prothrombotic effects of
CSA and TACþSIR. In addition, DF shows a consistent
although very mild effect of delaying the time of clot
formation when using whole blood, although these results
have been obtained with blood from healthy donors incu-
bated in vitro with the drugs under study and should not be
over-interpreted.
In conclusion, the calcineurin inhibitors studied here and
the combination of TAC and the mTOR inhibitor SIR exertedppressants and Effect of DF
þ DF
Control CSA TAC SIR TACþSIR
50.5 45.5 52.7 55.7 50.3
3.2 5.5 5.9 7.0 5.4
98.0 84.0 85.3 103.3 89.3
12.2 8.0 13.0 10.2 16.6
61.5 64.0 62.7 59.7 63.3
1.9 2.0 3.3 0.7 3.2
e time when the clot reached 20 mm; and the maximum clot ﬁrmness (MCF)
Figure 4. Modiﬁcations of the viscoelastic properties of clots. Bar diagrams
show the coagulation time (CT) (A) and clot formation time (CFT) (B) of
untreated whole-blood samples (C) or blood samples treated with cyclo-
sporine A (CSA), tacrolimus (TAC), sirolimus (SIR), or the combination of TAC
and SIR (TAC þ SIR) in the absence (black bars) and presence (gray bars) of DF.
Data are expressed as mean  SEM, n ¼ 5. None of the differences was
signiﬁcant.
A. Carmona et al. / Biol Blood Marrow Transplant 19 (2013) 1439e14451444proinﬂammatory action on the endothelium. Only CSA
exhibited both signiﬁcant proinﬂammatory and pro-
thrombotic actions. By contrast, these effects were not
observed in response to SIR. Interestingly, DF exhibited
reproducible protective effects to counteract the endothelial
aggression induced by the immunosuppressant compounds.ACKNOWLEDGMENTS
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